Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update

Reuters10-09

Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update

Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2574083157?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-09 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2574083157","market":"us","top_or_hot":-1,"title":"Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-09 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251009:nNDL7GrYwS:1","article_id":"2574083157","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2574083157","pubTimestamp":1760014528,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","APM":"知临集团"},"translate_title":"Aptorum Group宣布Laura A Philips博士加入董事会，作为与DiamiR Biosciences合并的一部分更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APM":0.9,"NDAQ":0.9},"content_text":"Aptorum Group announces addition of Dr Laura A Philips to board as part of merger with DiamiR Biosciences update\n    \n\n        Aptorum Group Limited is moving forward with its planned merger with DiamiR Biosciences Corp., expecting to close the transaction in the fourth quarter of 2025 following stockholder approval and customary closing conditions. As part of the agreement, DiamiR will become a wholly-owned subsidiary of Aptorum Group. The combined company will see an expanded board, with Dr. Laura A. Philips joining as an independent director at closing, Dr. Kira Sheinerman, DiamiR's co-founder and director, joining the board, and Dr. Alidad Mireskandari, DiamiR's CEO, taking an observer seat on the board and serving as President and Chief Operating Officer of the merged entity. The companies anticipate that the merger will strengthen their capabilities and presence in the development and commercialization of minimally invasive tests for early detection and monitoring of brain diseases.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9543006-en) on October 09, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2574083157","isCrawlerRequest":true}